(Q39082437)

8 September 2017

title

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor (English)

1 reference

8 September 2017

Constance King

1

1 reference

8 September 2017

Henry Diaz

2

1 reference

8 September 2017

Darlene Barnard

3

1 reference

8 September 2017

David Barda

4

1 reference

8 September 2017

David Clawson

5

1 reference

8 September 2017

Wayne Blosser

6

1 reference

8 September 2017

Karen Cox

7

1 reference

8 September 2017

Sherry Guo

8

1 reference

8 September 2017

Mark Marshall

9

1 reference

8 September 2017

publication date

10 October 2013

1 reference

Investigational New Drugs

8 September 2017

published in

1 reference

8 September 2017

volume

32

1 reference

8 September 2017

issue

2

1 reference

8 September 2017

page(s)

213-226

1 reference

New insights into checkpoint kinase 1 in the DNA damage response signaling network

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Unleashing Chk1 in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

ATR signalling: more than meeting at the fork

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Anticancer therapy with checkpoint inhibitors: what, where and when?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Chk1 inhibits replication factory activation but allows dormant origin firing in existing factories.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Chk1 regulates the density of active replication origins during the vertebrate S phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Chk1 promotes replication fork progression by controlling replication initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Structure-specific DNA endonuclease Mus81/Eme1 generates DNA damage caused by Chk1 inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

One-dimensional SDS gel electrophoresis of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Human Tousled like kinases are targeted by an ATM- and Chk1-dependent DNA damage checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Chk1 inhibitors for novel cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Targeting the S and G2 checkpoint to treat cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0036-7

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer

21 January 2018

1 reference

12 December 2020

A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress

1 reference

12 December 2020

Phosphorylation of histone H3 is required for proper chromosome condensation and segregation

1 reference

12 December 2020

DNA double-strand breaks in mammalian cells after exposure to intercalating agents

1 reference

12 December 2020

10.1007/S10637-013-0036-7

Identifiers

DOI

1 reference

8 September 2017

1 reference